Methods and compositions for treating and preventing respiratory related diseases and conditions with xylitol-headgroup lipid analogs

Patent metadata

Field	Value
Publication number	US-12472193-B2
Application number	US-202217669107-A
Country	US
Kind code	B2
Filing date	Feb 10, 2022
Priority date	Feb 27, 2017
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

The invention generally relates to methods to prevent and/or inhibit viral infection as well as to inhibit inflammation and/or pathogen infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual.

First claim

What is claimed:

1 . A method to inhibit respiratory syncytial virus (RSV) infection in an individual who has, or is at risk of developing RSV infection, the method comprising administering to the individual at least one xylitol lipid analog, wherein the amount of the xylitol lipid analog is effective to inhibit said viral infection, and wherein the xylitol lipid analog is selected from the group consisting of Dipalmitoleoyl-phosphatidylxylitol (16:1 DPPX), Dioleoyl-phosphatidylxylitol (DOPX), Palmitoyl-oleoyl-phosphatidylxylitol (POPX), and Dilinoleoyl-phosphatidylxylitol (18:2 DLPX).

2 . The method of claim 1 , wherein the viral infection activates Toll-like receptors (TLR) selected from the group consisting of: TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, TLR9, and TLR10.

3 . The method of claim 1 , wherein the individual is a neonatal infant.

4 . The method of claim 1 , wherein the xylitol lipid analog is administered to the individual prior to any indication of viral infection.

5 . The method of claim 1 , wherein the xylitol lipid analog is administered to the individual subsequent to identification of a symptom of or confirmation of viral infection of the individual.

6 . The method of claim 1 , wherein the xylitol lipid analog is administered as a homogeneous lipid preparation.

7 . The method of claim 1 , wherein the xylitol lipid analog is administered as a composition comprising a homogeneous lipid preparation of the xylitol lipid analog.

8 . The method of claim 1 , wherein the xylitol lipid analog is administered via respiratory tract of the individual.

9 . The method of claim 1 , wherein the xylitol lipid analog is administered via nasal passages of the individual.

10 . The method of claim 1 , wherein the xylitol lipid analog suppresses activation of at least one TLR selected from the group consisting of TLR1, TLR2, TLR3, TLR4, and TLR7.

11 . The method of claim 1 , wherein the xylitol lipid analog is administered in combination with at least one material selected from the group consisting of palmitoyl-oleoyl-phosphatidylglycerol (POPG), surfactant protein A (SP-A) and surfactant protein D (SP-D).

Assignees

• Nat Jewish Health

Inventors

• Voelker Dennis R

Classifications

• A61K9/0043

  Nose · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• A61K31/683 Primary

  Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols · CPC title